The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach. 2009

Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
Laboratoire d'Organogénèse Expérimentale/LOEX, Hôpital du Saint-Sacrement du Centre Hospitalier Affilié Universitaire de Québec, Quebec, Canada.

We set out to examine the pathophysiological mechanisms of fibrosis in diffuse systemic sclerosis (SSc) using a tissue engineering approach. Skin fibroblasts were isolated from lesional skin of SSc patients with a disease duration of less than 1 year (early-stage SSc) or more than 10 years (late-stage SSc). Fibroblasts were also isolated from non-lesional skin and compared with normal fibroblasts isolated from healthy adults. Cells were cultured using a tissue engineering method to reconstruct a human dermis, and histologically observed. Dermal thickness was measured, as it reflects the global and intrinsic capacity of cells to reconstitute matrix. Collagen I, MMP-1, and MMP activity were evaluated. Cells were treated with TGFbeta1 or CTGF during dermis formation to study their fibrogenic role. Clinical severity of skin involvement was measured by a modified Rodnan score. Thickness of the dermis generated with non-lesional early-stage SSc fibroblasts was similar to normal cells. In contrast, reconstructed dermis from lesional early-stage SSc fibroblasts and non-lesional late-stage SSc cells was thinner, while lesional late-stage SSc fibroblasts made a thicker dermis. Dermis was always thicker when produced with TGFbeta1-treated cells, except when lesional late-stage SSc fibroblasts from patients with high Rodnan skin scores were used. CTGF did not affect dermal thickness. Measurements of collagen I and collagenases in the culture medium of the various reconstructed dermis could explain some of the changes observed. We conclude that the fibrotic phenotype of SSc fibroblasts varies with disease duration and with severity of skin involvement, and this is clearly visualized during in vitro dermis reconstruction.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005260 Female Females
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D005355 Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. Cirrhosis,Fibroses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
January 2013, Methods in molecular biology (Clifton, N.J.),
Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
December 2015, Clinical immunology (Orlando, Fla.),
Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
February 2014, Experimental dermatology,
Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
January 2015, Clinical and experimental rheumatology,
Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
May 2024, Rheumatology (Oxford, England),
Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
July 2020, Journal of dermatological science,
Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
April 2024, Arthritis care & research,
Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
January 2013, Arthritis research & therapy,
Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
March 2017, Heart (British Cardiac Society),
Marie-Pier Corriveau, and Inès Boufaied, and Julie Lessard, and Stéphane Chabaud, and Jean-Luc Senécal, and Tamara Grodzicky, and Suzanne Chartier, and Yves Raymond, and Véronique J Moulin
February 2010, Rheumatology (Oxford, England),
Copied contents to your clipboard!